公开(公告)号：US20020094536A1

公开(公告)日：2002-07-18

申请号：US10028970

申请日：2001-12-28

Applicant: CELL THERAPEUTICS, INC.

Inventor： Alan Lofquist ,  Robert E. Finney ,  David Leung

IPC: C12Q001/68 ,  C12M001/34 ,  C12N015/00

CPC classification number: C12N15/10 ,  C12N15/1034 ,  C12N15/1082 ,  C12N15/85 ,  C12N15/902 ,  C12N2800/60 ,  C12N2840/206 ,  C12N2840/44

Abstract: A method for high-throughput, genomics analysis, to identify the therapeutic or diagnostic utility of genes, entails the use of a construct to disrupt a gene or alleles of a gene in cells of interest. Arrays of such cells can be used to monitor such disrupted cells phenotypically in the context, for example, of testing drug candidates. Polynucleotides that comprise part of the disrupted genes can be recovered from such nullknockoutnull cells, by virtue of an origin of replication or a host cell selection marker sequence that is part of the construct. The recovered polynucleotides can be used to identify the disrupted genes or to make homologous recombination vectors, which in turn can be employed to make multi-allele knockout cells.

Abstract translation: 用于识别基因的治疗或诊断效用的高通量，基因组学分析的方法需要使用构建体来破坏目的细胞中基因的基因或等位基因。 这种细胞的阵列可以用于在上下文中表型地监测这样的破坏细胞，例如测试候选药物。 可以通过复制起点或作为构建体一部分的宿主细胞选择标记序列从这种“敲除”细胞中回收构成部分破坏基因的多核苷酸。 回收的多核苷酸可用于鉴定破坏的基因或使同源重组载体，其又可用于制备多等位基因敲除细胞。

公开(公告)号：US20020107269A1

公开(公告)日：2002-08-08

申请号：US09984889

申请日：2001-10-31

Applicant: CELL THERAPEUTICS, INC.

Inventor： Lynn Bonham ,  J. Peter Klein ,  Robert E. Finney ,  David M. Hollenback ,  Scott A. Shaffer ,  Norina M. Tang ,  Thayer H. White ,  David W. Leung

IPC: A61K031/428 ,  A61K031/423 ,  A61K031/4184 ,  C07D277/60 ,  C07D263/56

CPC classification number: C07D263/57 ,  C07D235/18 ,  C07D277/66

Abstract: The invention relates to benzoxazoles and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening for LPAAT-null activity.

Abstract translation: 本发明涉及苯并恶唑及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述苯并恶唑治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。

公开(公告)号：US20040162288A1

公开(公告)日：2004-08-19

申请号：US10712900

申请日：2003-11-13

Applicant: Cell Therapeutics, Inc.

Inventor： Baoqing Gong ,  John Tulinsky ,  Lynn Bonham ,  J. Peter Klein ,  Robert E. Finney ,  David M. Hollenback ,  Scott A. Shaffer ,  Norina M. Tang ,  Thayer H. White ,  David W. Leung

IPC: A61K031/5377 ,  A61K031/53

CPC classification number: C07D251/70 ,  C07D251/50 ,  C07D251/52 ,  C07D251/54 ,  C07D251/58

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.

Abstract translation: 本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述三嗪治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。

公开(公告)号：US20020103195A1

公开(公告)日：2002-08-01

申请号：US09984888

申请日：2001-10-31

Applicant: CELL THERAPEUTICS,INC.

Inventor： Lynn Bonham ,  J. Peter Klein ,  Robert E. Finney ,  David M. Hollenback ,  Scott A. Shaffer ,  Norina M. Tang ,  Thayer H. White ,  David W. Leung

IPC: A61K031/5377 ,  A61K031/53 ,  C07D413/14 ,  C07D43/14

CPC classification number: C07D251/70 ,  C07D251/50 ,  C07D251/52 ,  C07D251/54 ,  C07D251/58

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.

Abstract translation: 本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述三嗪治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。